13/11/2025
A breakthrough discovery of a new cancer cell type could transform treatment approaches for children with aggressive leukaemia. Researchers from , Wellcome Sanger Institute, UCL and Addenbrooke’s Hospital have identified a new type of treatment-resistant cancer cell in children with T-cell acute lymphoblastic leukaemia (T-ALL).
By identifying a specific genetic marker, using tests already in routine use, clinicians may soon be able to predict which children will respond to chemotherapy, and which may require and alternative treatment approach from diagnosis.
Dr David O’Connor, co-senior author, Consultant Paediatric Haematologist at GOSH and Honorary Associate Professor at UCL, said:
“Until now, it has not been possible to tailor treatment for T-cell leukaemia in the same way as we can for B-cell leukaemia. Being able to identify children who will not respond to initial treatment on the day of diagnosis is of great importance.”
For children like Jacob, who was diagnosed with T-ALL leukaemia last year, and is now in remission after treatment at GOSH, this research represents hope for a future where treatment is more precise, effective and designed around every child.
🔗 Learn more and read the full article: https://tinyurl.com/3kkjm5xe